Heparin‐induced thrombocytopaenia · adults with CVCs
It is very uncertain whether heparin changes heparin‐induced thrombocytopaenia compared with normal saline solution locking (very low certainty).
1 finding from 1 review
Occlusion of CVC (combining participant and catheter as unit of analysis) Blood withdrawing · adults with CVCs
Heparin may leads to lower occlusion of CVC (combining participant, and catheter as unit of… compared with normal saline solution locking (low certainty).
1 finding from 1 review
Duration of catheter patency (days; combining participant and catheter as unit of analysis) Blood withdrawing · adults with CVCs
1 finding from 1 review
CVC‐related bloodstream infections (positive microbiological culture, participant as unit of analysis) · adults with CVCs
It is very uncertain whether heparin changes CVC‐related bloodstream infections (positive microbiological… compared with normal saline solution locking (very low certainty).
1 finding from 1 review
All‐cause mortality · adults with CVCs
It is very uncertain whether heparin changes mortality compared with normal saline solution locking (very low certainty).
1 finding from 1 review
Haemorrhage · adults with CVCs
It is very uncertain whether heparin changes haemorrhage from any site compared with normal saline solution locking (very low certainty).
1 finding from 1 review
All‐cause mortality · people undergoing bariatric surgery
1 finding from 1 review
VTE‐related mortality4 · people undergoing bariatric surgery
1 finding from 1 review
PE · people undergoing bariatric surgery
1 finding from 1 review
Deep vein thrombosis · people undergoing bariatric surgery
Heparin showed no clear difference in DVT compared with pentasaccharide (low certainty).
1 finding from 1 review
Thrombocytopenia · people undergoing bariatric surgery
It is very uncertain whether heparin changes adverse events (thrombocytopenia) compared with pentasaccharide (very low certainty).
1 finding from 1 review
Total VTE · people undergoing bariatric surgery
Heparin showed no clear difference in VTE compared with pentasaccharide (low certainty).
1 finding from 1 review
Major bleeding · people undergoing bariatric surgery
It is very uncertain whether heparin changes major bleeding compared with pentasaccharide (very low certainty).
1 finding from 1 review
All cause mortality (timing not specified) · people undergoing major amputation of the lower extremity
1 finding from 1 review
Adverse events (timing not specified) · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bleeding (timing not specified) · people undergoing major amputation of the lower extremity
1 finding from 1 review
Total VTE · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
DVT (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
PE (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity
Heparin showed no clear difference in PE (symptomatic, asymptomatic, non‐fatal) (timing not specified) compared with placebo (low certainty).
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (high certainty).
1 finding from 1 review